hVIVO announces new major holder

hVIVO plc

hVIVO plc (LON:HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has been notified of a change in major holdings.

On the 27th October 2022 the threshold in which notification is required was crossed when Allan Rankin purchased 20,702,209 shares in the company, which represents 3.09% voting rights.

The transaction completed on the 3rd of November 2022.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Find more news, interviews, share price & company profile here for:

Good news travels fast (but only if you make that happen). Share on:

Forum friendly shortlink: https://1lo.co/CHdNP

AIM All Share Index